07 Apr 2026

CRC Research Update — April 07, 2026

Creator: The CRC Digest
Published: 2026-04-07T12:01:18Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Chemotherapy exposure may lower tumor mutation burden in advanced CRC
Analysis of 88 patients with advanced microsatellite-stable colorectal cancer found that prior chemotherapy exposure was associated with reduced tumor mutation burden, suggesting treatment history may influence genomic profiling results. (Scientific Reports)
Phase I/II trial tests triple combination for RAS-mutant metastatic CRC
The RASTRIC trial evaluated lapatinib, binimetinib, and vinorelbine in patients with RAS-mutant metastatic colorectal cancer, reporting safety and efficacy results for this difficult-to-treat population. (British Journal of Cancer)
Phase I trial evaluates trastuzumab rezetecan for HER2-expressing GI cancers
Multicenter Phase I study assessed trastuzumab rezetecan in patients with HER2-expressing advanced gastric cancer, gastroesophageal junction adenocarcinoma, and colorectal cancer. (Journal of Clinical Oncology)
Methylated Septin9 shows promise for CRC diagnosis and recurrence monitoring
Study explored the clinical utility of liquid biopsy biomarker methylated Septin9 for colorectal cancer diagnosis, surgical efficacy evaluation, recurrence monitoring, and prognosis, comparing its performance to CEA and CA19-9. (Clinica Chimica Acta)
Primary care providers' awareness of early-onset CRC symptoms examined
Survey assessed primary care providers' knowledge of colorectal cancer symptoms and referral practices for patients under age 50, as incidence and death rates continue rising in this population. (Population Health Management)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Primary care providers surveyed on early-onset CRC awareness
Study examined PCPs' knowledge of CRC symptoms and referral practices for patients under 50, addressing the rising incidence in younger adults. (Population Health Management)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Liquid biopsy marker mSEPT9 evaluated for CRC screening and monitoring
Research assessed methylated Septin9 as a blood-based biomarker for colorectal cancer diagnosis, recurrence monitoring, and prognosis. (Clinica Chimica Acta)
AI-assisted imaging compared to standard linked color imaging for polyp detection
Randomized trial in Brazil compared linked color imaging versus AI-assisted LCI for detecting adenomas and sessile serrated lesions during colonoscopy. (Clinical Endoscopy)

Research continues advancing our understanding of CRC across screening, treatment, and early-onset disease.

CRC Research Update

Subscribe to The CRC Digest